Last reviewed: June 5, 2026
Last updated: June 5, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Glucagon-like peptide-1 (GLP-1) is a hormone your intestines naturally release after eating to regulate blood sugar and suppress appetite. When GLP-1 levels are optimized through medication, many people experience significant reductions in food cravings and sustained weight loss. PlexusDx specializes in precision GLP-1 therapy tailored to your metabolic profile and genetic predispositions.
What Are GLP-1 Hormones and How Do They Work?
GLP-1 is an incretin hormone released by intestinal cells in response to nutrients, particularly glucose. It binds to GLP-1 receptors throughout your body, triggering three key effects: slowing gastric emptying so food stays in your stomach longer, signaling satiety to your brain to reduce hunger, and stimulating insulin secretion to lower blood sugar naturally. This multi-mechanism action makes GLP-1 activation effective for both weight management and glycemic control in people with type 2 diabetes.
Your body produces GLP-1 naturally, but the amount and duration of this hormone depend on your genetics, diet, and metabolic health. Some individuals have genetic variations that reduce GLP-1 receptor sensitivity or efficiency, meaning they may need higher doses or adjunctive approaches to achieve results. PlexusDx's Precision Peptide Genetic Test identifies these key variants—including GLP1R rs6923761—so your treatment plan addresses your unique biology rather than relying on a one-size-fits-all approach.
GLP-1 and Blood Sugar Control in Type 2 Diabetes
Clinical trials have demonstrated that GLP-1 receptor agonists lower hemoglobin A1C (a measure of average blood sugar over three months) by approximately 1.5% to 2%, often accompanied by weight loss of 5% to 15% of body weight. This dual benefit occurs because GLP-1 medications increase insulin secretion when blood glucose is elevated while simultaneously reducing hepatic glucose production. For people with type 2 diabetes, this means better glucose stability without the hypoglycemia risk associated with older insulin therapies.
The cardiovascular benefits extend beyond blood sugar control. Large outcome trials have shown that GLP-1 therapies reduce the risk of major adverse cardiovascular events in people with existing heart disease or diabetes. PlexusDx compounded semaglutide injection therapy delivers these benefits while allowing dose titration tailored to your tolerance and metabolic response, all without the expense of brand-name medications.
GLP-1 Mechanisms for Weight Loss Beyond Appetite Suppression
While appetite reduction is the most noticeable effect, GLP-1 works through several pathways to promote weight loss. It increases energy expenditure by slightly elevating your resting metabolic rate, improves insulin sensitivity so your body requires less compensatory insulin, and reduces cravings for high-fat and high-sugar foods by altering reward signaling in the brain. Together, these mechanisms create a sustainable foundation for weight loss without extreme caloric restriction or prolonged hunger.
GLP-1 also slows gastric emptying—the rate at which food leaves your stomach—which extends feelings of fullness and naturally reduces portion sizes. People on GLP-1 therapy often report that they feel satisfied with smaller meals and experience fewer between-meal cravings. Studies show average weight loss of 8% to 22% of baseline body weight depending on the specific GLP-1 agent, dose consistency, and lifestyle modifications like nutrition and movement.
Personalized GLP-1 Therapy at PlexusDx: Why One Size Does Not Fit All
PlexusDx recognizes that GLP-1 response varies significantly between individuals due to genetic differences in hormone pathways, receptor sensitivity, and metabolic enzyme function. Your genetic profile influences how effectively you will respond to semaglutide injection or other GLP-1 compounds, and whether adjunctive peptides like tirzepatide might accelerate your results. The Precision Peptide Genetic Test evaluates 14 distinct pathways and 49 peptides, including critical variants in GLP1R, GIPR, FTO, and MC4R genes, revealing your individual predispositions for weight loss and metabolic optimization.
PlexusDx compounded semaglutide injection begins at $149 per month and remains flat across all dose levels—your dose may increase as your body adapts, but your price will not. This transparent pricing model, combined with HSA and FSA eligibility and availability in all 50 states without insurance requirements, removes common barriers to accessing effective GLP-1 therapy. All PlexusDx medications are sourced from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade quality and sterility.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the difference between GLP-1 and tirzepatide?
GLP-1 agonists like semaglutide activate only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, often producing greater weight loss and blood sugar reduction in clinical trials.
How much weight can I expect to lose with GLP-1 therapy?
Average weight loss ranges from 5% to 22% of baseline body weight over 12 months, depending on the specific medication, adherence, and lifestyle factors. Individual results vary based on genetics, starting weight, and metabolic health.
Is compounded semaglutide as effective as brand-name Ozempic or Wegovy?
PlexusDx compounded semaglutide contains the same active ingredient and is manufactured in licensed 503A compounding pharmacies meeting strict FDA guidelines. Efficacy is equivalent to brand medications, but PlexusDx pricing starts at $149/mo—typically 60% to 75% less expensive than brand-name versions.
What are the common side effects of GLP-1 therapy?
Most common side effects are gastrointestinal: nausea, vomiting, constipation, or diarrhea, typically mild and temporary during dose escalation. Serious side effects are rare but may include acute pancreatitis or thyroid concerns in susceptible individuals.
How does the Precision Peptide Genetic Test improve my GLP-1 treatment?
The test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R that predict your response to GLP-1 therapy and whether dual-peptide approaches like tirzepatide might be more effective for you.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When Does Semaglutide Start Working? A Detailed Look at Its Timeline and Effects
When Does Semaglutide Start Working? A Detailed Look at Its Timeline and Effects